Relay Therapeutics, Inc. $RLAY Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC grew its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) by 77.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,573 shares of the company’s stock after acquiring an additional 28,700 shares during the period. Janus Henderson Group PLC’s holdings in Relay Therapeutics were worth $652,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in RLAY. KBC Group NV acquired a new position in Relay Therapeutics during the first quarter valued at $34,000. Torren Management LLC acquired a new stake in Relay Therapeutics during the 4th quarter worth about $30,000. Smartleaf Asset Management LLC raised its stake in shares of Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after buying an additional 3,287 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Relay Therapeutics during the 4th quarter valued at about $46,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Relay Therapeutics by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock valued at $71,000 after buying an additional 1,757 shares during the period. Institutional investors and hedge funds own 96.98% of the company’s stock.

Insider Activity at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $16.97, for a total transaction of $3,176,156.11. Following the completion of the sale, the chief financial officer owned 177,461 shares of the company’s stock, valued at $3,011,513.17. The trade was a 51.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Donald A. Bergstrom sold 93,456 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $16.94, for a total transaction of $1,583,144.64. Following the transaction, the insider owned 418,557 shares of the company’s stock, valued at approximately $7,090,355.58. This trade represents a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 427,356 shares of company stock valued at $7,461,240. 5.04% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Canaccord Genuity Group began coverage on Relay Therapeutics in a research note on Thursday, July 16th. They issued a “buy” rating and a $29.00 target price on the stock. Zacks Research downgraded Relay Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Citizens Jmp upped their price objective on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research report on Monday. The Goldman Sachs Group raised their price objective on shares of Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Relay Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.58.

Relay Therapeutics Price Performance

Relay Therapeutics stock opened at $19.94 on Tuesday. The stock has a market capitalization of $4.37 billion, a PE ratio of -12.70 and a beta of 1.69. The business has a 50 day simple moving average of $17.83 and a 200-day simple moving average of $13.61. Relay Therapeutics, Inc. has a 12 month low of $3.15 and a 12 month high of $20.79.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. On average, equities research analysts anticipate that Relay Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.